{"id":"cloxacillin","rwe":[{"pmid":"41899487","year":"2026","title":"Anti-Biofilm Activity of Combinations of Cinnamic Acid and Its Derivatives with Cloxacillin Against Methicillin-Resistant Staphylococcus epidermidis.","finding":"","journal":"Current issues in molecular biology","studyType":"Clinical Study"},{"pmid":"41807780","year":"2026","title":"A collagen hydrogel-based 3D Heparg model for enhanced hepatocyte function and assessment of cholestatic drug-induced liver injury.","finding":"","journal":"Archives of toxicology","studyType":"Clinical Study"},{"pmid":"41789926","year":"2026","title":"Pharmacokinetic drug-drug interactions with flucloxacillin and other isoxazolyl penicillins: A systematic literature review and practical guide.","finding":"","journal":"British journal of clinical pharmacology","studyType":"Clinical Study"},{"pmid":"41785411","year":"2026","title":"Prevalence of acute kidney injury in Staphylococcus aureus bacteraemia treated with cloxacillin: a retrospective cohort study.","finding":"","journal":"Infectious diseases (London, England)","studyType":"Clinical Study"},{"pmid":"41766520","year":"2026","title":"Is current guidance for cloxacillin prophylaxis dosages in hip and knee arthroplasty adequate? Evidence from a prospective Swedish cohort.","finding":"","journal":"The Journal of antimicrobial chemotherapy","studyType":"Clinical Study"}],"tags":[{"label":"cloxacillin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"J01CF02","category":"atc"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Acute bacterial sinusitis","category":"indication"},{"label":"Continuation Therapy for Acute Osteomyelitis","category":"indication"},{"label":"Continuation Therapy for Chronic Osteomyelitis","category":"indication"},{"label":"Infection due to Staphylococcus aureus","category":"indication"},{"label":"Infection of skin AND/OR subcutaneous tissue","category":"indication"},{"label":"Lower respiratory tract infection","category":"indication"},{"label":"Glaxosmithkline","category":"company"},{"label":"Approved 1970s","category":"decade"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":315.69,"date":"","count":108,"signal":"Drug reaction with eosinophilia and systemic symptoms","source":"DrugCentral FAERS","actionTaken":"Reported 108 times (LLR=316)"},{"llr":268.962,"date":"","count":189,"signal":"Acute kidney injury","source":"DrugCentral FAERS","actionTaken":"Reported 189 times (LLR=269)"},{"llr":100.886,"date":"","count":43,"signal":"Agranulocytosis","source":"DrugCentral FAERS","actionTaken":"Reported 43 times (LLR=101)"},{"llr":91.919,"date":"","count":42,"signal":"Cholestasis","source":"DrugCentral FAERS","actionTaken":"Reported 42 times (LLR=92)"},{"llr":85.646,"date":"","count":37,"signal":"Tubulointerstitial nephritis","source":"DrugCentral FAERS","actionTaken":"Reported 37 times (LLR=86)"},{"llr":76.581,"date":"","count":38,"signal":"Rash maculo-papular","source":"DrugCentral FAERS","actionTaken":"Reported 38 times (LLR=77)"},{"llr":71.46,"date":"","count":34,"signal":"Hepatocellular injury","source":"DrugCentral FAERS","actionTaken":"Reported 34 times (LLR=71)"},{"llr":59.447,"date":"","count":30,"signal":"Eosinophilia","source":"DrugCentral FAERS","actionTaken":"Reported 30 times (LLR=59)"},{"llr":56.05,"date":"","count":11,"signal":"Nephritis allergic","source":"DrugCentral FAERS","actionTaken":"Reported 11 times (LLR=56)"},{"llr":50.774,"date":"","count":29,"signal":"Jaundice","source":"DrugCentral FAERS","actionTaken":"Reported 29 times (LLR=51)"},{"llr":49.124,"date":"","count":13,"signal":"Vascular purpura","source":"DrugCentral FAERS","actionTaken":"Reported 13 times (LLR=49)"},{"llr":47.989,"date":"","count":56,"signal":"Thrombocytopenia","source":"DrugCentral FAERS","actionTaken":"Reported 56 times (LLR=48)"},{"llr":47.064,"date":"","count":10,"signal":"Allergy to metals","source":"DrugCentral FAERS","actionTaken":"Reported 10 times (LLR=47)"},{"llr":46.852,"date":"","count":10,"signal":"Iodine allergy","source":"DrugCentral FAERS","actionTaken":"Reported 10 times (LLR=47)"},{"llr":45.78,"date":"","count":25,"signal":"Toxic epidermal necrolysis","source":"DrugCentral FAERS","actionTaken":"Reported 25 times (LLR=46)"}],"commonSideEffects":[],"contraindications":["Infectious mononucleosis","Kidney disease","Pseudomembranous enterocolitis"]},"trials":[],"aliases":[],"company":"GSK","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CLOXACILLIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:40:43.476500+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:40:49.060767+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CLOXACILLIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:40:49.521131+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Penicillin-binding protein inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:40:50.568286+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200388/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:40:50.226765+00:00"}},"allNames":"methocillin s","offLabel":[],"synonyms":["cloxacillin","Methocillin S","cloxacillin sodium","cloxacillin sodium salt","cloxacillin benzathine"],"timeline":[{"date":"1974-09-17","type":"positive","source":"DrugCentral","milestone":"FDA approval (Glaxosmithkline)"}],"aiSummary":"Methocillin S (Cloxacillin) is a small molecule antibiotic developed by GlaxoSmithKline, currently owned by the same company. It is classified as a cloxacillin and was FDA-approved in 1974 for various bacterial infections, including those caused by Staphylococcus aureus. The drug is available as a generic medication, with multiple manufacturers, and is off-patent. Methocillin S is used to treat a range of infections, including acute bacterial sinusitis, osteomyelitis, and skin infections. It is not patented and is widely available.","approvals":[{"date":"1974-09-17","orphan":false,"company":"GLAXOSMITHKLINE","regulator":"FDA"}],"brandName":"Methocillin S","ecosystem":[{"indication":"Acute bacterial sinusitis","otherDrugs":[{"name":"alatrofloxacin","slug":"alatrofloxacin","company":"Pfizer"},{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"azithromycin","slug":"azithromycin","company":""}],"globalPrevalence":null},{"indication":"Continuation Therapy for Acute Osteomyelitis","otherDrugs":[{"name":"dicloxacillin","slug":"dicloxacillin","company":"Wyeth Ayerst"},{"name":"oxacillin","slug":"oxacillin","company":"Sandoz"}],"globalPrevalence":null},{"indication":"Continuation Therapy for Chronic Osteomyelitis","otherDrugs":[{"name":"dicloxacillin","slug":"dicloxacillin","company":"Wyeth Ayerst"},{"name":"oxacillin","slug":"oxacillin","company":"Sandoz"}],"globalPrevalence":null},{"indication":"Infection due to Staphylococcus aureus","otherDrugs":[{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"azithromycin","slug":"azithromycin","company":""},{"name":"benzylpenicillin","slug":"benzylpenicillin","company":"Pfizer"}],"globalPrevalence":null},{"indication":"Infection of skin AND/OR subcutaneous tissue","otherDrugs":[{"name":"alatrofloxacin","slug":"alatrofloxacin","company":"Pfizer"},{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"amphotericin B","slug":"amphotericin-b","company":"Apothecon"}],"globalPrevalence":null},{"indication":"Lower respiratory tract infection","otherDrugs":[{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"aztreonam","slug":"aztreonam","company":"Bristol Myers Squibb"},{"name":"cefaclor","slug":"cefaclor","company":""},{"name":"cefalotin","slug":"cefalotin","company":"Lilly"}],"globalPrevalence":null},{"indication":"Pharyngitis","otherDrugs":[{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"amphotericin B","slug":"amphotericin-b","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"bacampicillin","slug":"bacampicillin","company":""}],"globalPrevalence":null},{"indication":"Sinusitis","otherDrugs":[{"name":"amphotericin B","slug":"amphotericin-b","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"bacampicillin","slug":"bacampicillin","company":""},{"name":"demeclocycline","slug":"demeclocycline","company":"Lederle"}],"globalPrevalence":null}],"mechanism":{"novelty":"Follow-on","modality":"Small Molecule","drugClass":"cloxacillin","explanation":"","oneSentence":"","technicalDetail":"Cloxacillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), which are essential for the cross-linking of peptidoglycan layers in the bacterial cell wall."},"commercial":{"launchDate":"1974","_launchSource":"DrugCentral (FDA 1974-09-17, GLAXOSMITHKLINE)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/720","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CLOXACILLIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CLOXACILLIN","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T10:14:41.787345","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:40:51.852397+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"dicloxacillin","drugSlug":"dicloxacillin","fdaApproval":"1968-04-22","genericCount":5,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"meticillin","drugSlug":"meticillin","fdaApproval":"","relationship":"same-class"},{"drugName":"oxacillin","drugSlug":"oxacillin","fdaApproval":"1971-04-08","genericCount":15,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"nafcillin","drugSlug":"nafcillin","fdaApproval":"1965-10-11","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"cloxacillin","indications":{"approved":[{"name":"Acute bacterial sinusitis","source":"DrugCentral","snomedId":75498004,"regulator":"FDA"},{"name":"Continuation Therapy for Acute Osteomyelitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Continuation Therapy for Chronic Osteomyelitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Infection due to Staphylococcus aureus","source":"DrugCentral","snomedId":406602003,"regulator":"FDA"},{"name":"Infection of skin AND/OR subcutaneous tissue","source":"DrugCentral","snomedId":19824006,"regulator":"FDA"},{"name":"Lower respiratory tract infection","source":"DrugCentral","snomedId":50417007,"regulator":"FDA"},{"name":"Pharyngitis","source":"DrugCentral","snomedId":405737000,"regulator":"FDA"},{"name":"Sinusitis","source":"DrugCentral","snomedId":36971009,"regulator":"FDA"},{"name":"Staphylococcal meningitis","source":"DrugCentral","snomedId":12166008,"regulator":"FDA"},{"name":"Staphylococcal pneumonia","source":"DrugCentral","snomedId":22754005,"regulator":"FDA"},{"name":"Staphylococcal septicemia","source":"DrugCentral","snomedId":111821004,"regulator":"FDA"},{"name":"Staphylococcus Aureus Bronchitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Staphylococcus Aureus Urinary Tract Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Staphylococcus Epidermidis Urinary Tract Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"}],"offLabel":[{"name":"Bacterial endocarditis","source":"DrugCentral","drugName":"CLOXACILLIN","evidenceCount":171,"evidenceLevel":"strong"},{"name":"Cholangitis","source":"DrugCentral","drugName":"CLOXACILLIN","evidenceCount":1,"evidenceLevel":"emerging"},{"name":"Diabetic Foot Infection Due to Gram-Positive Bacteria","source":"DrugCentral","drugName":"CLOXACILLIN","evidenceCount":1,"evidenceLevel":"emerging"},{"name":"Pyrexia of unknown origin","source":"DrugCentral","drugName":"CLOXACILLIN","evidenceCount":7,"evidenceLevel":"emerging"}],"pipeline":[]},"drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"dicloxacillin","brandName":"dicloxacillin","genericName":"dicloxacillin","approvalYear":"1968","relationship":"same-class"},{"drugId":"meticillin","brandName":"meticillin","genericName":"meticillin","approvalYear":"","relationship":"same-class"},{"drugId":"oxacillin","brandName":"oxacillin","genericName":"oxacillin","approvalYear":"1971","relationship":"same-class"},{"drugId":"nafcillin","brandName":"nafcillin","genericName":"nafcillin","approvalYear":"1965","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03246360","phase":"NA","title":"Pharmacological Comparison of Continuous and Intermittent Infusions of Cloxacillin","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2017-11-23","conditions":["Infection","Methicillin Susceptible Staphylococcus Aureus Infection","Cloxacillin Treatment"],"enrollment":12,"completionDate":"2018-09-18"},{"nctId":"NCT06712641","phase":"PHASE4","title":"Aminoglycosides in Early Sepsis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Akershus","startDate":"2026-04","conditions":["Sepsis"],"enrollment":1900,"completionDate":"2033-05"},{"nctId":"NCT05398679","phase":"PHASE4","title":"Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis","status":"RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-08-17","conditions":["Endocarditis Infective"],"enrollment":360,"completionDate":"2027-12-30"},{"nctId":"NCT06848387","phase":"PHASE4","title":"Unbound Cloxacillin Concentrations During Continuous Infusion","status":"RECRUITING","sponsor":"Emeli Månsson","startDate":"2026-01-14","conditions":["Staphylococcal Infections"],"enrollment":25,"completionDate":"2027-12"},{"nctId":"NCT02701608","phase":"PHASE3","title":"Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Staphylococcus","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2016-02-29","conditions":["Infective Endocarditis"],"enrollment":162,"completionDate":"2024-12-04"},{"nctId":"NCT03248063","phase":"NA","title":"Non-inferiority Trial Comparing Cloxacillin vs Cefazolin in Methicillin-susceptible Staphylococcus Aureus Bacteremia","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-09-05","conditions":["Bacteremia Due to Methicillin Susceptible Staphylococcus Aureus"],"enrollment":315,"completionDate":"2025-03-10"},{"nctId":"NCT01543334","phase":"","title":"Antibiotic Concentrations Among Critically Ill Patients","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2012-03","conditions":["Administration of Antibiotics in Intensive Care Units"],"enrollment":98,"completionDate":"2012-04-01"},{"nctId":"NCT05137119","phase":"PHASE4","title":"Staphylococcus Aureus Network Adaptive Platform Trial","status":"RECRUITING","sponsor":"University of Melbourne","startDate":"2022-02-16","conditions":["Staphylococcus Aureus Bacteremia"],"enrollment":8000,"completionDate":"2028-12-01"},{"nctId":"NCT07186894","phase":"","title":"Cefazolin Versus Antistaphylococcal Penicillins for Methicillin Susceptible Staphylococcus Aureus Bacteremia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Central Hospital, Nancy, France","startDate":"2000-01-01","conditions":["Bacteriemia","Methicillin Susceptible Staphylococcus Aureus (MSSA) Infection"],"enrollment":5000,"completionDate":"2026-09-01"},{"nctId":"NCT04563325","phase":"PHASE4","title":"Oral-only Antibiotics for Bone and Joint Infections in Children","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2020-09-15","conditions":["Osteomyelitis","Septic Arthritis","Bone Infection","Joint Infection","Bone and Joint Infection"],"enrollment":180,"completionDate":"2024-08-05"},{"nctId":"NCT05530174","phase":"NA","title":"Effect of Single vs Multiple Prophylactic Antibiotic Doses on PJI Following Primary THA in Patients With a Fracture","status":"ACTIVE_NOT_RECRUITING","sponsor":"Soren Overgaard","startDate":"2022-09-01","conditions":["Fracture of Hip","Total Hip Arthroplasty","Prosthetic-joint Infection","Fracture Acetabular"],"enrollment":2000,"completionDate":"2025-04-01"},{"nctId":"NCT06726395","phase":"PHASE4","title":"Comparison of Cloxacillin and Benzylpenicillin in Penicillin Susceptible S. Aureus Bacteraemia","status":"RECRUITING","sponsor":"Region Skane","startDate":"2025-03-10","conditions":["Staphylococcus Aureus Bacteraemia","Staphylococcal Bacteraemia","Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)","Staphylococcus (S.) Aureus Infection"],"enrollment":420,"completionDate":"2028-07"},{"nctId":"NCT05530551","phase":"NA","title":"Effect of Single vs Multiple Prophylactic Antibiotic Doses on PJI Following Primary THA in Patients With OA","status":"ACTIVE_NOT_RECRUITING","sponsor":"Soren Overgaard","startDate":"2022-09-01","conditions":["Osteoarthritis, Hip","Total Hip Arthroplasty","Prosthetic-joint Infection"],"enrollment":20000,"completionDate":"2025-03-01"},{"nctId":"NCT05899140","phase":"PHASE4","title":"Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial","status":"RECRUITING","sponsor":"Frieder Schaumburg","startDate":"2024-03-15","conditions":["Skin Infection","Staphylococcal Infections","Staphylococcus Aureus Infection"],"enrollment":100,"completionDate":"2026-07-31"},{"nctId":"NCT06695832","phase":"","title":"Adjunctive Fosfomycin for Treatment of Staphylococcus Aureus Bacteraemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hospital Universitari de Bellvitge","startDate":"2024-11-01","conditions":["Staphylococcus Aureus Bacteremia"],"enrollment":369,"completionDate":"2025-01-31"},{"nctId":"NCT04410003","phase":"PHASE1","title":"Metabolic and Metagenomic Effects of Intestinal Microbiome Repopulation in Unexplained Atherosclerosis","status":"RECRUITING","sponsor":"Western University, Canada","startDate":"2020-06-02","conditions":["Atherosclerosis","Intestinal Microbiome"],"enrollment":100,"completionDate":"2025-07-30"},{"nctId":"NCT06505135","phase":"PHASE1","title":"Stem Cell Treatment for Regeneration of the Rotator Cuff (Lipo-Cuff Study)","status":"ENROLLING_BY_INVITATION","sponsor":"University of Southern Denmark","startDate":"2024-09-03","conditions":["Rotator Cuff Tears","Rotator Cuff Injuries","Rotator Cuff Tear Arthropathy"],"enrollment":30,"completionDate":"2026-09"},{"nctId":"NCT02814916","phase":"PHASE3","title":"Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-03-30","conditions":["Methicillin-Resistant Staphylococcus Aureus","Bacterial Infections","Staphylococcal Skin Infections"],"enrollment":199,"completionDate":"2024-01-01"},{"nctId":"NCT06336824","phase":"PHASE3","title":"Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia","status":"RECRUITING","sponsor":"Clinical Research Centre, Malaysia","startDate":"2024-06-28","conditions":["Staphylococcus Aureus Bacteremia"],"enrollment":290,"completionDate":"2025-06"},{"nctId":"NCT06454643","phase":"NA","title":"Gentamicin in Cardiac Surgery","status":"COMPLETED","sponsor":"Al-Rasheed University College","startDate":"2020-01-01","conditions":["Cardiac Infection"],"enrollment":50,"completionDate":"2021-01-01"},{"nctId":"NCT05156437","phase":"PHASE4","title":"Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)","status":"ENROLLING_BY_INVITATION","sponsor":"Vinay Badhwar","startDate":"2022-03-16","conditions":["Endocarditis"],"enrollment":20,"completionDate":"2024-10"},{"nctId":"NCT03108690","phase":"PHASE4","title":"Therapeutic Drug Monitoring and Continuous Infusion of Beta-lactam Antibiotics in Patients With Bacteraemia","status":"WITHDRAWN","sponsor":"Sara Thønnings","startDate":"2017-10-01","conditions":["Bacteremia"],"enrollment":0,"completionDate":"2023-03-09"},{"nctId":"NCT05578482","phase":"PHASE4","title":"Staphylococcus Aureus and The Skin Microbiome During Flare And Resolution Of Atopic Dermatitis","status":"UNKNOWN","sponsor":"Jacob Pontoppidan Thyssen","startDate":"2022-10-24","conditions":["Atopic Dermatitis","Atopic Dermatitis Eczema","Atopic Dermatitis Flare"],"enrollment":45,"completionDate":"2023-05"},{"nctId":"NCT03632642","phase":"PHASE4","title":"Penicillin Against Flucloxacillin Treatment Evaluation","status":"WITHDRAWN","sponsor":"The University of Queensland","startDate":"2019-07-01","conditions":["Staphylococcus Aureus"],"enrollment":0,"completionDate":"2020-07"},{"nctId":"NCT02334124","phase":"NA","title":"Comparing the Intravenous Treatment of Skin Infections in Children, Home Versus Hospital","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2015-01","conditions":["Cellulitis"],"enrollment":190,"completionDate":"2022-11"},{"nctId":"NCT01876628","phase":"PHASE4","title":"Adjunctive Clindamycin for Cellulitis: C4C Trial.","status":"COMPLETED","sponsor":"University Hospitals Bristol and Weston NHS Foundation Trust","startDate":"2013-10","conditions":["Cellulitis"],"enrollment":410,"completionDate":"2016-03"},{"nctId":"NCT05073627","phase":"PHASE1","title":"The Effect of Dicloxacillin on Oral Absorption of Drugs","status":"COMPLETED","sponsor":"University of Southern Denmark","startDate":"2022-02-07","conditions":["Healthy Volunteers","Drug-drug Interaction"],"enrollment":12,"completionDate":"2022-06-22"},{"nctId":"NCT03959345","phase":"PHASE4","title":"Efficacy of Cloxacillin and Fosfomycin Combination Versus Cloxacillin Monotherapy in Patients With MSSA Bacteremia","status":"TERMINATED","sponsor":"Miquel Pujol","startDate":"2019-05-31","conditions":["Methicillin Susceptible Staphylococcus Aureus Septicemia"],"enrollment":215,"completionDate":"2022-02-24"},{"nctId":"NCT04840641","phase":"PHASE1","title":"Flucloxacillin as an Inducer of CYP-enzymes","status":"COMPLETED","sponsor":"University of Southern Denmark","startDate":"2021-03-25","conditions":["Healthy Volunteers","Drug Drug Interaction"],"enrollment":14,"completionDate":"2021-12-28"},{"nctId":"NCT05142891","phase":"","title":"Renal Tolerance of Amoxicillin and Cloxacillin Combination","status":"UNKNOWN","sponsor":"University Hospital, Strasbourg, France","startDate":"2021-10-15","conditions":["Endocarditis","Acute Kidney Injury"],"enrollment":50,"completionDate":"2022-10-30"},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":["Osteomyelitis"],"enrollment":11,"completionDate":"2018-11-07"},{"nctId":"NCT01792804","phase":"PHASE3","title":"Staphylococcus Aureus Bacteremia Antibiotic Treatment Options","status":"COMPLETED","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2013-12","conditions":["Staphylococcus Aureus Infection"],"enrollment":215,"completionDate":"2020-03-26"},{"nctId":"NCT00433342","phase":"PHASE1","title":"The Effect of Antimicrobial Therapy on the Serum Level of P-cresol in Peritoneal Dialysis Patients","status":"TERMINATED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2006-03","conditions":["Chronic Kidney Disease"],"enrollment":9,"completionDate":"2020-04"},{"nctId":"NCT02208063","phase":"PHASE3","title":"A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial","status":"TERMINATED","sponsor":"Cumberland Pharmaceuticals","startDate":"2014-12","conditions":["Bacteremia"],"enrollment":121,"completionDate":"2018-04-12"},{"nctId":"NCT04141787","phase":"PHASE4","title":"Ceftriaxone as Home IV for Staph Infections","status":"UNKNOWN","sponsor":"Vancouver Island Health Authority","startDate":"2019-07-11","conditions":["Staphylococcal Infections","Osteomyelitis","CNS Infection","Septic Arthritis","Diabetic Foot Infection","Vertebral Osteomyelitis","Abscess","Coagulase Negative Staphylococcal Infection"],"enrollment":310,"completionDate":"2024-03-30"},{"nctId":"NCT00062647","phase":"PHASE2","title":"Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia","status":"COMPLETED","sponsor":"Cumberland Pharmaceuticals","startDate":"2003-08","conditions":["Gram-Positive Bacterial Infections"],"enrollment":60,"completionDate":"2006-08"},{"nctId":"NCT00077675","phase":"PHASE2","title":"Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)","status":"COMPLETED","sponsor":"Cumberland Pharmaceuticals","startDate":"2004-02","conditions":["Infections, Gram-positive Bacterial"],"enrollment":201,"completionDate":"2004-09"},{"nctId":"NCT00061633","phase":"PHASE2","title":"Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)","status":"COMPLETED","sponsor":"Cumberland Pharmaceuticals","startDate":"2003-06","conditions":["Infections, Gram-Positive Bacterial","Abscess","Burns","Cellulitis","Ulcer","Wound Infections"],"enrollment":169,"completionDate":"2004-01"},{"nctId":"NCT02365493","phase":"PHASE3","title":"Combination Antibiotic Therapy for Methicillin Resistant Staphylococcus Aureus Infection","status":"TERMINATED","sponsor":"Menzies School of Health Research","startDate":"2015-08-26","conditions":["Methicillin-Resistant Staphylococcus Aureus"],"enrollment":358,"completionDate":"2018-10-24"},{"nctId":"NCT02993575","phase":"","title":"Pharmacokinetics of Flucloxacillin Given by Continuous or Intermittent Infusion to ICU Patients","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2017-06-01","conditions":["Bacterial Infections"],"enrollment":30,"completionDate":"2018-04-01"},{"nctId":"NCT01104662","phase":"PHASE4","title":"Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment","status":"TERMINATED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2010-04-19","conditions":["Complicated Skin and Skin Structure Infections","S. Aureus Bacteremia","Renal Impairment"],"enrollment":92,"completionDate":"2012-06-12"},{"nctId":"NCT00711802","phase":"PHASE4","title":"Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2008-07-23","conditions":["Skin Diseases, Infectious"],"enrollment":396,"completionDate":"2013-10-11"},{"nctId":"NCT02983890","phase":"PHASE1","title":"Dicloxacillin: Clinical Relevance of Drug-drug Interactions by Induction of Drug Metabolism.","status":"COMPLETED","sponsor":"Per Damkier","startDate":"2016-10-06","conditions":["Healthy"],"enrollment":12,"completionDate":"2017-10-01"},{"nctId":"NCT00428844","phase":"PHASE2","title":"Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2007-06-26","conditions":["Osteomyelitis"],"enrollment":75,"completionDate":"2010-06-23"},{"nctId":"NCT01191840","phase":"PHASE2","title":"Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection","status":"COMPLETED","sponsor":"Duke University","startDate":"2011-02","conditions":["Bacteremia"],"enrollment":509,"completionDate":"2017-03-04"},{"nctId":"NCT01770769","phase":"NA","title":"Undisplaced Femoral Neck Fractures in the Elderly: A Trial Comparing Internal Fixation to Hemiarthroplasty","status":"UNKNOWN","sponsor":"University Hospital, Akershus","startDate":"2012-02-06","conditions":["Femoral Neck Fractures"],"enrollment":220,"completionDate":"2020-02-06"},{"nctId":"NCT02032654","phase":"PHASE4","title":"Duration of ANtibiotic Therapy for CEllulitis","status":"TERMINATED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2014-08-26","conditions":["Cellulitis","Erysipelas"],"enrollment":151,"completionDate":"2017-09-25"},{"nctId":"NCT00358371","phase":"PHASE1","title":"Bioavailability Of Flucloxacillin Capsules (250 mg and 500 mg)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-01-06","conditions":["Infections, Bacterial"],"enrollment":24,"completionDate":"2005-02-08"},{"nctId":"NCT03120663","phase":"","title":"Target Attainment and Pharmacokinetics of Antimicrobials in Non-critically Ill Surgery Patients (TAPAS)","status":"UNKNOWN","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2016-11-30","conditions":["Surgery"],"enrollment":120,"completionDate":"2018-09-30"},{"nctId":"NCT02922686","phase":"PHASE4","title":"Penicillin for the Emergency Department Outpatient Treatment of CELLulitis","status":"UNKNOWN","sponsor":"Royal College of Surgeons, Ireland","startDate":"2016-12","conditions":["Cellulitis","Wound Infection","Abscess"],"enrollment":414,"completionDate":"2019-12"},{"nctId":"NCT01582360","phase":"","title":"2012_PharmacoCRRT-study:Pharmacokinetics of Anti-infectives in Critically Ill Patients in Need of Continuous Renal Replacement Therapy (CRRT)","status":"UNKNOWN","sponsor":"Oslo University Hospital","startDate":"2013-05","conditions":["Critically Ill","Acute Renal Failure","Acute Kidney Injury"],"enrollment":640,"completionDate":"2018-01"},{"nctId":"NCT01875263","phase":"PHASE3","title":"Efficacy of a Short-term Sequential Therapy in Non-complicated Catheter Related Bacteremia by Methicillin- Susceptible S.Aureus.","status":"TERMINATED","sponsor":"Fundación Pública Andaluza Progreso y Salud","startDate":"2013-05","conditions":["Staphylococcus"],"enrollment":1,"completionDate":"2014-11"},{"nctId":"NCT00772447","phase":"PHASE3","title":"China Registration Study in Patients With Skin Infections","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-09","conditions":["Skin Diseases","Infectious"],"enrollment":265,"completionDate":"2010-09"},{"nctId":"NCT01587768","phase":"","title":"WEUKBRE5555: IMI PROTECT(Work Package 2): Liver Injury & Antibiotics","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11","conditions":["Infections, Bacterial"],"enrollment":1,"completionDate":"2014-07"},{"nctId":"NCT00423982","phase":"PHASE4","title":"Rifampin Combination Therapy Versus Monotherapy in Early Staphylococcal Infections After Total Hip and Knee Arthroplasty","status":"UNKNOWN","sponsor":"Oslo University Hospital","startDate":"2006-04","conditions":["Prosthesis-related Infections","Staphylococcal Infections"],"enrollment":100,"completionDate":"2014-12"},{"nctId":"NCT01184872","phase":"PHASE3","title":"Study to Compare Efficacy and Safety of Daptomycin in Elderly Patients With Complicated Skin and Soft Tissue Infections","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-03","conditions":["Infections"],"enrollment":120,"completionDate":"2011-03"},{"nctId":"NCT00037050","phase":"PHASE3","title":"Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria","status":"COMPLETED","sponsor":"Pfizer","startDate":"2002-04","conditions":["Bacterial Infections","Gram-Positive Bacterial Infections","Bacteremia"],"enrollment":739,"completionDate":"2005-07"},{"nctId":"NCT00716183","phase":"PHASE2,PHASE3","title":"Use of Probiotic Lactobacilli for the Treatment of Lactational Mastitis","status":"COMPLETED","sponsor":"Universidad Complutense de Madrid","startDate":"2008-07","conditions":["Mastitis"],"enrollment":300,"completionDate":"2009-05"},{"nctId":"NCT00885300","phase":"NA","title":"Cloxacillin as Prevention of Double Lumen Infection in Hemodialysis Patients","status":"COMPLETED","sponsor":"Shiraz University of Medical Sciences","startDate":"2008-01","conditions":["Double Lumen Infection","Hemodialysis"],"enrollment":100,"completionDate":"2008-09"},{"nctId":"NCT00857480","phase":"PHASE1","title":"Evaluation of the PK of NRL972 Following Pre- and co-Administration of Ursodeoxycholic Acid and Cloxacillin","status":"COMPLETED","sponsor":"Norgine","startDate":"2006-06","conditions":["Hepatic Cirrhosis"],"enrollment":12,"completionDate":"2006-10"},{"nctId":"NCT00405158","phase":"NA","title":"Study of Acupuncture and Care Interventions for the Treatment of Breast Inflammation During Breastfeeding","status":"COMPLETED","sponsor":"Karlstad University","startDate":"2002-01","conditions":["Mastitis"],"enrollment":210,"completionDate":"2004-03"},{"nctId":"NCT00129688","phase":"NA","title":"Once-Daily Amikacin Plus Cloxacillin in Febrile Neutropenic Children","status":"COMPLETED","sponsor":"Khon Kaen University","startDate":"2002-04","conditions":["Neutropenia","Cancer","Fever"],"enrollment":166,"completionDate":"2004-06"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NUI":"N0000147781","MMSL":"407","NDDF":"002691","UNII":"O6X5QGC2VB","VUID":"4019689","CHEBI":"CHEBI:49566","VANDF":"4017893","INN_ID":"1533","RXNORM":"1043213","UMLSCUI":"C0009077","chemblId":"CHEMBL1200388","ChEMBL_ID":"CHEMBL891","KEGG_DRUG":"D07733","DRUGBANK_ID":"DB01147","PDB_CHEM_ID":" CXN","PUBCHEM_CID":"6098","SNOMEDCT_US":"16492006","IUPHAR_LIGAND_ID":"11126","SECONDARY_CAS_RN":"7081-44-9","MESH_DESCRIPTOR_UI":"D003023"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1974-","companyName":"GSK","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"40%"},"publicationCount":2163,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"J01CF02","allCodes":["J01CF02"]},"biosimilarFilings":[],"originalDeveloper":"Glaxosmithkline","recentPublications":[{"date":"2026 Mar 23","pmid":"41899487","title":"Anti-Biofilm Activity of Combinations of Cinnamic Acid and Its Derivatives with Cloxacillin Against Methicillin-Resistant Staphylococcus epidermidis.","journal":"Current issues in molecular biology"},{"date":"2026 Mar 10","pmid":"41807780","title":"A collagen hydrogel-based 3D Heparg model for enhanced hepatocyte function and assessment of cholestatic drug-induced liver injury.","journal":"Archives of toxicology"},{"date":"2026 Mar 6","pmid":"41789926","title":"Pharmacokinetic drug-drug interactions with flucloxacillin and other isoxazolyl penicillins: A systematic literature review and practical guide.","journal":"British journal of clinical pharmacology"},{"date":"2026 Mar 5","pmid":"41785411","title":"Prevalence of acute kidney injury in Staphylococcus aureus bacteraemia treated with cloxacillin: a retrospective cohort study.","journal":"Infectious diseases (London, England)"},{"date":"2026 Feb 2","pmid":"41766520","title":"Is current guidance for cloxacillin prophylaxis dosages in hip and knee arthroplasty adequate? Evidence from a prospective Swedish cohort.","journal":"The Journal of antimicrobial chemotherapy"}],"companionDiagnostics":[],"genericManufacturers":3,"_genericFilersChecked":true,"genericManufacturerList":["Apothecon","Glaxosmithkline","Teva"],"status":"approved","companyName":"GSK","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"1974","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1974-09-17T00:00:00.000Z","mah":"GLAXOSMITHKLINE","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1974-09-17T00:00:00.000Z","mah":"GLAXOSMITHKLINE","brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1974-09-17T00:00:00.000Z","mah":"GLAXOSMITHKLINE","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1974-09-17T00:00:00.000Z","mah":"GLAXOSMITHKLINE","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1974-09-17T00:00:00.000Z","mah":"GLAXOSMITHKLINE","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1974-09-17T00:00:00.000Z","mah":"GLAXOSMITHKLINE","brand_name_local":null,"application_number":""},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:40:51.852397+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}